CLINICAL TRIALS PROFILE FOR MOXIFLOXACIN HYDROCHLORIDE

505(b)(2) Clinical Trials for Moxifloxacin Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT01589497 ↗	Essentiality of INH in TB Therapy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2015-06-30	Tuberculosis (TB) disease is caused by bacteria that have infected the lung. TB bacteria are very small living agents that are spread by coughing and can be killed by taking TB drugs. To kill these TB bacteria TB patients have to take a combination of four drugs for 2 months and then two drugs for a further 4 months. During the first 2 months patients take rifampicin, isoniazid, ethambutol, and pyrazinamide. After that patients take only isoniazid and rifampicin for a further 4 months, making a total of 6 months therapy. In A5307 the investigators wanted to test a new combination of drugs to see if the investigators could treat TB faster in the future. Studies in animals have suggested that one of the four drugs, isoniazid, only works for a few days and may not be needed after the first two doses of TB treatment to kill the TB bacteria. After that its effects wear off to the point that it may even interfere with the other drugs. The investigators wanted to see if stopping isoniazid early, or using moxifloxacin, a different drug, instead could treat TB faster. This study was the first time that this type of regimen without isoniazid had been tested in humans. If the investigators could show that isoniazid stops working after a few days, the investigators could then try to see if they could possibly make a better tuberculosis treatment in the future.
New Combination	NCT01589497 ↗	Essentiality of INH in TB Therapy	Completed	AIDS Clinical Trials Group	Phase 2	2015-06-30	Tuberculosis (TB) disease is caused by bacteria that have infected the lung. TB bacteria are very small living agents that are spread by coughing and can be killed by taking TB drugs. To kill these TB bacteria TB patients have to take a combination of four drugs for 2 months and then two drugs for a further 4 months. During the first 2 months patients take rifampicin, isoniazid, ethambutol, and pyrazinamide. After that patients take only isoniazid and rifampicin for a further 4 months, making a total of 6 months therapy. In A5307 the investigators wanted to test a new combination of drugs to see if the investigators could treat TB faster in the future. Studies in animals have suggested that one of the four drugs, isoniazid, only works for a few days and may not be needed after the first two doses of TB treatment to kill the TB bacteria. After that its effects wear off to the point that it may even interfere with the other drugs. The investigators wanted to see if stopping isoniazid early, or using moxifloxacin, a different drug, instead could treat TB faster. This study was the first time that this type of regimen without isoniazid had been tested in humans. If the investigators could show that isoniazid stops working after a few days, the investigators could then try to see if they could possibly make a better tuberculosis treatment in the future.
New Indication	NCT03257423 ↗	Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects	Enrolling by invitation	Helsinki University Central Hospital	N/A	2017-04-04	Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings. On the other hand, antibiotic therapies have been shown to have an effect on the normal gut microbiota and are considered an increasing global health threat underlining the importance of evaluating both short- and long-term effects of the antimicrobial treatment in old and new indications. The aims of this randomized prospective study are: 1. To evaluate the possible role and differences in the microbiological etiology of complicated and uncomplicated appendicitis. 2. To determine the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment (AMT) 3. To evaluate the effects of the duration of the hospital stay on the AMR reservoir of the gut microbiota.

All Clinical Trials for Moxifloxacin Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00062231 ↗	Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer	Terminated	European Organisation for Research and Treatment of Cancer - EORTC	N/A	2002-04-01	RATIONALE: Antibiotics such as amoxicillin, ciprofloxacin, and moxifloxacin may be effective in preventing or controlling fever and neutropenia in patients with cancer. It is not yet known whether moxifloxacin alone is more effective than amoxicillin combined with ciprofloxacin in treating neutropenia and fever. PURPOSE: This randomized clinical trial is studying how well moxifloxacin works and compares it to ciprofloxacin together with amoxicillin in treating neutropenia and fever in patients with cancer.

Clinical Trial Conditions for Moxifloxacin Hydrochloride

Condition Name

Condition Name for Moxifloxacin Hydrochloride
Intervention	Trials
Healthy	92
Healthy Volunteers	31
Tuberculosis	23

Condition MeSH

Condition MeSH for Moxifloxacin Hydrochloride
Intervention	Trials
Tuberculosis	58
Tuberculosis, Pulmonary	33
Cataract	24

Clinical Trial Locations for Moxifloxacin Hydrochloride

Trials by Country

Trials by Country for Moxifloxacin Hydrochloride
Location	Trials
United States	512
South Africa	113
Germany	100
China	89
United Kingdom	60

Trials by US State

Trials by US State for Moxifloxacin Hydrochloride
Location	Trials
Texas	57
California	35
Florida	32
Arizona	31
Maryland	28

Clinical Trial Progress for Moxifloxacin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Moxifloxacin Hydrochloride
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	7
PHASE2	4

Clinical Trial Status

Clinical Trial Status for Moxifloxacin Hydrochloride
Clinical Trial Phase	Trials
Completed	365
Recruiting	64
Not yet recruiting	28

Clinical Trial Sponsors for Moxifloxacin Hydrochloride

Sponsor Name

Sponsor Name for Moxifloxacin Hydrochloride
Sponsor	Trials
Bayer	34
GlaxoSmithKline	20
Pfizer	18

Sponsor Type

Sponsor Type for Moxifloxacin Hydrochloride
Sponsor	Trials
Other	476
Industry	442
NIH	16

Last updated: July 24, 2026

xifloxacin Hydrochloride Clinical Trials Update, Market Analysis, and Sales Projections (2026-2031)
Moxifloxacin hydrochloride is a widely marketed fluoroquinolone antibiotic with mature safety and resistance narratives. Publicly disclosed clinical development activity in new, stand-alone drug applications is limited versus its established position in respiratory and ocular indications. Near-term market dynamics are driven more by guideline adherence, payer access, formulary competition from other antibiotics, and generic penetration than by late-stage registration milestones.

What clinical trials are active for moxifloxacin hydrochloride in 2024–2026?

Answer: Late-stage, product-registration trials for moxifloxacin hydrochloride are sparse, with activity skewed toward formulation, dosing regimen comparisons, specialty delivery systems (notably ocular), and postmarketing/real-world evidence rather than new chemical entity development.

Trial types showing momentum

• Comparative efficacy and safety studies against other antibiotics for community-acquired respiratory infections (CAP), acute bacterial sinusitis, and infectious conjunctivitis/keratitis protocols.
• Ocular-administration studies that evaluate penetration, tolerability, and adherence to dosing schedules.
• Resistance surveillance-linked studies that correlate outcomes with susceptibility patterns and local antibiograms.

What typically limits new “big” trials

• The drug’s long history reduces the value of fresh placebo-controlled trials where standard-of-care comparisons dominate.
• Generics constrain sponsor incentives for broad new development unless the program is tied to a differentiated formulation, route, or label expansion.

Are there any late-stage (Phase 3) moxifloxacin trials expected to change the label?

Answer: No widely indexed, clearly public Phase 3 “label-changing” program for systemic moxifloxacin hydrochloride is identifiable from standard public registries at this time, based on the absence of prominent, late-stage enrollment disclosures that lead to FDA supplemental approvals.

Where label expansion is most plausible

• Ocular indications that can be supported by relatively small, targeted trials under FDA’s antibiotic development pathways.
• Narrower subpopulations tied to microbiology endpoints, adherence, or safety in special cohorts (geriatrics, renal impairment, comorbidity).

What is the current market for moxifloxacin hydrochloride by indication?

Answer: The core market is systemic use for respiratory and ENT infections and localized use in ophthalmology. Revenue is split between branded originator legacy supply and largely generic-driven volume economics.

Indication demand structure

• Respiratory/ENT: community-acquired respiratory infections, acute bacterial sinusitis, and related bacterial indications where fluoroquinolones remain a guideline option for selected patients.
• Ophthalmology: bacterial conjunctivitis and keratitis-like protocols using topical fluoroquinolone regimens where moxifloxacin is used as a standard option in many formularies.

Market pricing reality

• Branded revenue contracts over time as generics take share.
• Total demand is stable-to-moderate due to antibiotic stewardship constraints, with usage governed by resistance concerns and guideline positioning.

How is antibiotic stewardship affecting moxifloxacin volume and mix?

Answer: Stewardship pressures reduce unnecessary fluoroquinolone use and push prescribers toward narrower-spectrum alternatives when clinically appropriate. That effect is more visible in community settings and for less severe presentations, and it is less acute in ophthalmology where topical protocols follow different constraints.

Practical impact on forecasting

• Volumes likely grow slower than unit conversions in total antibiotic categories.
• Mix shifts can favor topical or regimen-specific products where guideline preference remains.

Who are the competitive substitutes for moxifloxacin hydrochloride?

Answer: Competition comes from other fluoroquinolones and broader classes used in respiratory and ocular care, with strongest substitution at the level of regimen selection rather than molecule-level exclusivity.

Systemic competitive set

• Respiratory cephalosporins, penicillins with beta-lactamase inhibitors, macrolides (where appropriate), and other fluoroquinolones.
• Local formulary preferences and resistance patterns determine whether prescribers choose a fluoroquinolone first-line or only for specific patients.

Ocular competitive set

• Other topical fluoroquinolones with similar spectrum and dosing patterns.
• Alternative antibiotic classes depending on resistance and safety messaging.

How much do generic moxifloxacin products influence revenue projections?

Answer: Generic entry is the dominant driver of price erosion and margin compression. Moxifloxacin’s market is mature enough that projections must assume continued substitution to generics and reduced brand premium.

Forecast implication

• Even if prescription volume holds, revenue growth is capped by declining net pricing.
• Market growth is more dependent on total-treated populations, guideline adherence, and payer coverage than on innovation.

Sales projection (2026–2031): base, upside, and downside scenarios

Answer: Revenue growth is expected to be low single-digit under base-case assumptions and could be flat-to-down under stronger stewardship or resistance-driven restrictions.

Scenario framework (how to model)

• Volume growth: constrained by stewardship and substitution to narrower agents.
• Price: driven by generic net pricing, tender dynamics, and competitive intensity.
• Mix: topical ophthalmology can stabilize mix versus systemic declines.

Projection bands (directional, for planning)

• Base case (2026–2031): modest CAGR in low single digits in global sales, driven by volume stability and partial mix support.
• Downside: flat revenue or modest decline if formularies further restrict fluoroquinolone use and resistance narratives intensify.
• Upside: low positive growth if ocular indications capture incremental share or if stewardship guidance stabilizes around existing pathways.

What manufacturing and IP barriers could affect supply and pricing?

Answer: For an established generic molecule, barriers are typically regulatory compliance, quality management, and manufacturing capacity rather than patent exclusivity.

Common operational levers

• Bioequivalence and formulation consistency requirements.
• GMP inspection outcomes that can temporarily affect supply continuity and tender pricing.

What is the Orange Book status of moxifloxacin hydrochloride?

Answer: Multiple moxifloxacin hydrochloride formulations and strengths are typically listed on the FDA Orange Book because both brand-originator and generic ANDA products exist. The relevant business question for market timing is which specific formulation strength/route has the last remaining patent or exclusivity and whether any listed patents are actively litigated.

What patents protect moxifloxacin hydrochloride products?

Answer: Patent protection for moxifloxacin hydrochloride largely reflects legacy composition-of-matter and any formulation/method-of-use or process patents associated with specific marketed formulations. In a mature market, the practical risk is not the molecule-level patent but the remaining protection status of particular dosage forms and releases.

Patent estate characteristics in mature antibiotics

• Limited remaining impact of broad composition patents.
• More meaningful protection at the formulation, polymorph, or manufacturing process level if any extensions or product-specific patents remain for certain strengths.

Are there any Paragraph IV or biosimilar challenges affecting moxifloxacin?

Answer: Paragraph IV challenges are plausible in generic moxifloxacin product lines historically, but they are typically not a major current driver of market change at the molecule level given the extensive generic penetration.

Biosimilar risk

• Not applicable. Moxifloxacin is a small molecule antibiotic, not a biologic.

What FDA regulatory pathway considerations matter most for moxifloxacin?

Answer: For generics, the central regulatory requirements are ANDA approval with bioequivalence and chemistry-manufacturing controls. For ocular products, topical quality and performance characteristics matter more than for systemic products.

Key regulatory constraints in practice

• Risk management for class safety signals associated with fluoroquinolones (labeling constraints affect prescribing, not approval likelihood).
• Risk evaluation and mitigation work (as applicable) shapes how sponsors and payers view tolerability and monitoring requirements.

Which companies hold meaningful share in moxifloxacin supply?

Answer: Market share is fragmented across multiple generic manufacturers and distributors. The largest revenue share depends on geography, tender cycles, and formulation availability rather than a single dominant innovator entity.

How to project share

• Use distribution strength and national formulary placement.
• Track tender outcomes for systemic tablets/solutions and ophthalmic drops/ointment.

How does moxifloxacin hydrochloride compare with ciprofloxacin and levofloxacin for commercial positioning?

Answer: Compared with ciprofloxacin and levofloxacin, moxifloxacin often holds a niche based on spectrum and perceived respiratory utility, but all are subject to fluoroquinolone class-level stewardship pressure. Commercial performance hinges on payer coverage and local resistance patterns.

Competitive differentiation that affects prescribing

• Guideline placement for selected respiratory infections.
• Ocular preference in topical protocols based on clinician habits and product availability.

Key takeaways

• Moxifloxacin hydrochloride is a mature antibiotic market where clinical trial intensity is not a primary driver of near-term growth; stewardship, resistance narratives, and generic net pricing are.
• Market outlook through 2031 is best modeled with low single-digit base-case growth and flat-to-downside risk if formulary restrictions tighten.
• Patent and exclusivity strategy is formulation- and strength-specific; molecule-level protection is generally not the key market timing lever.
• Competitive dynamics are dominated by generic substitution and tender-based pricing rather than brand innovation.

FAQs

1. What are the most common current indications for moxifloxacin hydrochloride in practice?
2. How do fluoroquinolone stewardship restrictions typically affect outpatient versus inpatient moxifloxacin use?
3. What formulation differences (systemic vs ophthalmic) matter most for clinical and commercial performance?
4. What dosing regimen constraints can influence adherence and persistence for moxifloxacin products?
5. How should tender-based contracting be incorporated into moxifloxacin revenue forecasts?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. ClinicalTrials.gov. Moxifloxacin hydrochloride studies (database query results). National Library of Medicine.
3. FDA labeling and safety communications for fluoroquinolone antibiotics. U.S. Food and Drug Administration.